The many, highly specific, biological therapies for immune-based diseases create a need for valid preclinical animal models. The wide immunological gap between human beings and laboratory mouse or rat models makes many disease models in these species invalid. In this review, we report a non-human-primate model of chronic multiple sclerosis (MS)-experimental autoimmune encephalitis (EAE) in the common marmoset (Callithrix jacchus)-that can help bridge this wide gap. The genetic and immunological similarity of marmosets and human beings and the clinical and neuropathological similarity of the EAE model to MS provide a unique experimental platform for research into basic immunopathogenetic mechanisms and for the development of more effective t...
Aging Western societies are facing an increasing prevalence of chronic autoimmune-mediated inflammat...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...
The efficacy of many new immunomodulatory therapies for multiple sclerosis (MS) patients has often b...
Despite years of intensive research into multiple sclerosis (MS) scientists have not yet succeeded i...
The attrition rate of new drugs for central nervous system diseases including multiple sclerosis (MS...
Introduction: The translation of scientific discoveries made in animal models into effective treatme...
textabstractMultiple sclerosis (MS) is a major cause of disability in young adults affecting approxi...
Due to their genetic and immunological proximity to humans, the common marmoset, Callithrix jacchus,...
Multiple sclerosis (MS) is one of the most intensively studied immune-based inflammatory diseases (I...
New drugs often fail in the translation from the rodent experimental autoimmune encephalomyelitis (E...
The phylogenetic proximity between non-human primate species and humans is reflected by a high degre...
The increasing prevalence of chronic autoimmune-mediated inflammatory disorders (AIMIDs) in aging hu...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
The experimental autoimmune encephalitis (EAE) model is used for preclinical research into the patho...
Aging Western societies are facing an increasing prevalence of chronic autoimmune-mediated inflammat...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...
The efficacy of many new immunomodulatory therapies for multiple sclerosis (MS) patients has often b...
Despite years of intensive research into multiple sclerosis (MS) scientists have not yet succeeded i...
The attrition rate of new drugs for central nervous system diseases including multiple sclerosis (MS...
Introduction: The translation of scientific discoveries made in animal models into effective treatme...
textabstractMultiple sclerosis (MS) is a major cause of disability in young adults affecting approxi...
Due to their genetic and immunological proximity to humans, the common marmoset, Callithrix jacchus,...
Multiple sclerosis (MS) is one of the most intensively studied immune-based inflammatory diseases (I...
New drugs often fail in the translation from the rodent experimental autoimmune encephalomyelitis (E...
The phylogenetic proximity between non-human primate species and humans is reflected by a high degre...
The increasing prevalence of chronic autoimmune-mediated inflammatory disorders (AIMIDs) in aging hu...
Experimental autoimmune encephalomyelitis in the common marmoset, a nonhuman primate species (Callit...
The experimental autoimmune encephalitis (EAE) model is used for preclinical research into the patho...
Aging Western societies are facing an increasing prevalence of chronic autoimmune-mediated inflammat...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...